Study Shows Multiple Infliximab Biosimilar Switches are Effective for Patients with IBD
April 21st 2023A study in Scotland found that multiple successive changes from originator infliximab to biosimilars effective and safe for patients with irritable bowel disease (IBD), irrespective of the number of switches (single, double, and triple).